Ancremonam

DB19710InvestigationalSmall molecule

Ancremonam is a small molecule drug. The usage of the INN stem '-monam' in the name indicates that Ancremonam is a monobactam antibiotic. Ancremonam is under investigation in clinical trial... Ancremonam is under investigation in clinical trial NCT03377426 (LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Urinary Tract Infection (cUTI)).

Formula / weight: C₁₆H₁₈N₆O₁₀S₂ · 518.47 g/mol (avg)
Code names: BOS-228 · LYS-228

Resolves to

Compound

UNII29H7N9XI1BCAS1810051-96-7ChEMBLCHEMBL4206129ChEBI756634PubChem118379834

Structure

InChIKeyFWTGYTRQUBRVDW-NRABZWKMSA-NSMILESNC1=NC(=CS1)C(=N\OC1(CC1)C(O)=O)\C(=O)N[C@H]1[C@@H](CN2CCOC2=O)N(C1=O)S(O)(=O)=O

Targets

P0AD68ftsI

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Ancremonam, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account